The market for Amniocentesis Needles is expected to reach US$ 205.8 Mn in 2027.
The amniocentesis needles market is expected to increase from US$ 156.4 million in 2018 to US$ 205.8 million by 2027 at a compound annual growth rate (CAGR) of 3.1% from 2019 to 2027. Amniocentesis is frequently performed in prenatal diagnosis to identify any chromosomal abnormalities, neural tube defects, and fetal infections during pregnancy. Rising public health awareness and the implementation of effective health guidelines pertaining to obstetrics and gynecology drive the amniocentesis needles market's growth.
100 to 150 mm needles are spearheading the type segment of the amniocentesis needle market. The ergonomic features associated with it, such as optimal length and availability in different gauges, increase its popularity among healthcare professionals for the collection of amniotic fluid. Larger than 150 mm needles are gaining huge traction as they enhance safety and ensure fewer needle punctures during transabdominal amniocentesis fluid collection in obese pregnant women with increased transabdominal thickness.
Hospitals are dominating the end-user segment for amniocentesis needles. The chief contributing factors influencing its market growth are rising public health awareness regarding prenatal diseases and the effective diagnosis and availability of affordable healthcare services pertaining to obstetrics and gynecology. Diagnostic centers will be projecting impressive growth during the forecast period owing to the availability of skilled workers and advanced equipment utilized in prenatal diagnosis.
In 2018, North America held a market share of 34.7% and led the regional segment for amniocentesis needles. The important criteria responsible for its dominating market growth are the rising popularity of prenatal diagnosis in pregnant women and the domicile of market leaders in the region, such as CooperSurgical, Inc., Smiths Group, Plc., Medline Industries, Inc., Becton Dickinson & Company, etc. Europe held a market share of 31.5%, primarily due to the effective implementation of health guidelines pertaining to obstetrics and gynecology. The supportive regulatory environment provided by the European Medical Agency for the manufacture and sale of amniocentesis needles. Asia Pacific represents 25.2% of the market share, owing to a rise in disposable income, developing healthcare infrastructure, and a highly competitive environment for major players due to emerging local manufacturers of amniocentesis needles.
This research report presents the analysis of each segment from 2017 to 2027, considering 2018 as the base year for the research. The compound annual growth rate (CAGR) for each of the respective segments is calculated for the forecast period from 2019 to 2027.
The market is segmented by type, end user, and geography.
Medical device companies manufacturing amniocentesis needles are Becton Dickinson & Company, Biopsybell Srl, Cook Medical Incorporated, CooperSurgical, Inc., Laboratoire CCD, Tsunami Medical Srl, Medline Industries, Inc., Ri.mos. Srl, Smiths Group, Plc., and Rocket Medical, Plc.
The market for Amniocentesis Needles is expected to reach US$ 205.8 Mn in 2027.
The Amniocentesis Needles market is expected to see significant CAGR growth over the coming years,at 3.1%.
The report is forecasted from 2019-2027.
The base year of this report is 2018.
Becton Dickinson & Company,Biopsybell Srl,Cook Medical Incorporated,CooperSurgical, Inc.,Laboratoire Ccd are some of the major players in the global market.